Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Cescon, David W."'
Autor:
Fuentes-Antrás J; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.; Experimental Therapeutics Unit, Hospital Clínico San Carlos, IDISSC and CIBERONC, 28040 Madrid, Spain., Martínez-Rodríguez A; Molecular Oncology Laboratory, IdISSC, 28040 Madrid, Spain., Guevara-Hoyer K; Department of Clinical Immunology, Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain.; Cancer Immunomonitoring and Immune-Mediated Diseases Unit, Hospital Clínico San Carlos, IdISSC, 28040 Madrid, Spain., López-Cade I; Experimental Therapeutics Unit, Hospital Clínico San Carlos, IDISSC and CIBERONC, 28040 Madrid, Spain.; Molecular Oncology Laboratory, IdISSC, 28040 Madrid, Spain., Lorca V; Molecular Oncology Laboratory, IdISSC, 28040 Madrid, Spain., Pascual A; Department of Pathology, Hospital Clínico San Carlos, 28040 Madrid, Spain., de Luna A; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain., Ramírez-Ruda C; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain., Swindell J; Medical Affairs Division, Sysmex Inostics, Inc., Baltimore, MD 21205, USA., Flores P; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain., Lluch A; INCLIVA Research Institute, Hospital Clínico Universitario de Valencia, 46010 Valencia, Spain., Cescon DW; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON M5S A18, Canada., Pérez-Segura P; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain., Ocaña A; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.; Experimental Therapeutics Unit, Hospital Clínico San Carlos, IDISSC and CIBERONC, 28040 Madrid, Spain., Jones F; Medical Affairs Division, Sysmex Inostics, Inc., Baltimore, MD 21205, USA., Moreno F; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain., García-Barberán V; Molecular Oncology Laboratory, IdISSC, 28040 Madrid, Spain., García-Sáenz JÁ; Department of Medical Oncology, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain.
Publikováno v:
International journal of molecular sciences [Int J Mol Sci] 2023 Jul 13; Vol. 24 (14). Date of Electronic Publication: 2023 Jul 13.
Autor:
Algorashi I; Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada; King Fahad Medical City, Riyadh, Saudi Arabia., Goldvaser H; Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada; Davidoff Cancer Centre, Beilinson Hospital and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel., Ribnikar D; Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada., Cescon DW; Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada., Amir E; Division of Medical Oncology, Princess Margaret Cancer Centre and the University of Toronto, Toronto, Canada. Electronic address: eitan.amir@uhn.ca.
Publikováno v:
Cancer treatment reviews [Cancer Treat Rev] 2018 Nov; Vol. 70, pp. 138-143. Date of Electronic Publication: 2018 Aug 24.
Autor:
Goldvaser H; Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Research Unit, Albacete University Hospital, Albacete, Spain; Translational Oncology Laboratory, Regional Center for Biomedical Research, Castilla La Mancha University, Albacete, Spain., Barnes TA; Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Research Unit, Albacete University Hospital, Albacete, Spain; Translational Oncology Laboratory, Regional Center for Biomedical Research, Castilla La Mancha University, Albacete, Spain., Šeruga B; Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Research Unit, Albacete University Hospital, Albacete, Spain; Translational Oncology Laboratory, Regional Center for Biomedical Research, Castilla La Mancha University, Albacete, Spain., Cescon DW; Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Research Unit, Albacete University Hospital, Albacete, Spain; Translational Oncology Laboratory, Regional Center for Biomedical Research, Castilla La Mancha University, Albacete, Spain., Ocaña A; Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Research Unit, Albacete University Hospital, Albacete, Spain; Translational Oncology Laboratory, Regional Center for Biomedical Research, Castilla La Mancha University, Albacete, Spain., Ribnikar D; Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Research Unit, Albacete University Hospital, Albacete, Spain; Translational Oncology Laboratory, Regional Center for Biomedical Research, Castilla La Mancha University, Albacete, Spain., Amir E; Division of Medical Oncology, University of Toronto and Princess Margaret Cancer Centre, Toronto, Canada; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia; Research Unit, Albacete University Hospital, Albacete, Spain; Translational Oncology Laboratory, Regional Center for Biomedical Research, Castilla La Mancha University, Albacete, Spain.
Publikováno v:
Journal of the National Cancer Institute [J Natl Cancer Inst] 2018 Jan 01; Vol. 110 (1).
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Goldvaser, Hadar, Barnes, Tristan A., Šeruga, Boštjan, Cescon, David W., Ocaña, Alberto, Ribnikar, Domen, Amir, Eitan
Publikováno v:
JNCI: Journal of the National Cancer Institute; 1/7/2018, Vol. 110 Issue 1, p1-39, 9p